KRAS and cancer: The findings provide evidence that the Rho/MRTF pathway is activated in the presence of Kras mutations, not only in stellate cells and cancer associated fibroblasts but also in some immune cells that may rely on this pathway to maintain their immunosuppressive phenotype.